Paracetamol UNIFLASH for Buccal Use Phase III Trial in Acute Pain Due to a Tooth Extraction

PHASE3CompletedINTERVENTIONAL
Enrollment

407

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

November 8, 2022

Study Completion Date

November 10, 2022

Conditions
Acute Pain
Interventions
DRUG

Paracetamol Uniflash 125mg

Oromucosal solution 1.25 mL for buccal use

DRUG

Panadol 500 MG Oral Tablet X1

Tablet masked in capsule

DRUG

Panadol 500 MG Oral Tablet X2

Tablet masked in capsule

DRUG

Placebo

Dummy treatment

Trial Locations (20)

15706

Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela

30003

Faculty of Medicine of the UNIVERSITY OF MURCIA, Murcia

33075

CHU de Bordeaux, Bordeaux

34070

CHU Montpellier, Montpellier

50425

NZOZ Akademicka Poliklinika Stomatologiczna, Wroclaw

63003

CHRU de Clermont Ferrand, Clermont-Ferrand

92213

Oral Surgery Department, Central Clinical Hospital, Lodz

92700

Hôpital Louis Mourier, Colombes

Unknown

CHU de Strasbourg, Strasbourg

Università degli Studi di Milano, Milan

Department of maxilla facial Surgery -University of Udine, Udine

University Central Stomatology GDANSK, Gdansk

Dental Practice, Lodz

Oral surgery Medical University of Lublin, Lublin

AW Clinic, Warsaw

Hospital Odontológico Universitat Barcelona, Barcelona

Facultad de Odontología de la Universidad de Granada, Granada

Instituto Profesor Sada, Madrid

Hospital Universitario Virgen del Rocio, Seville

08022

Centro Médico Teknon - Grupo Quironsalud, Barcelona

All Listed Sponsors
collaborator

AIXIAL Development

UNKNOWN

lead

Unither Pharmaceuticals, France

INDUSTRY

NCT04640376 - Paracetamol UNIFLASH for Buccal Use Phase III Trial in Acute Pain Due to a Tooth Extraction | Biotech Hunter | Biotech Hunter